Ditte Beck Jepsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ditte Beck Jepsen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jesper Ryg
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Lars Erik Matzen
Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark
3 shared publications - Tahir Masud
Department of Geriatric Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
3 shared publications - Karen Andersen-Ranberg
Geriatric Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
2 shared publications - Niklas Rye Jørgensen
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
2 shared publications - Stinus Hansen
Department of Endocrinology, Hospital South West Jutland, Esbjerg, Denmark
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-8
Falls, frailty, and fractures in the elderly
Falls are among the most common and serious events in older adults and are closely associated with frailty. Falls frequently result in fractures, leading to substantial consequences for health, physical function, quality of life, independence, social isolation, and increased mortality. Although falls are often perceived as an inevitable part of ageing, this review finds that falls can be largely prevented through targeted exercise and their consequences mitigated through a systematic, multidisciplinary approach.
- 6 July 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-8
Open AccessFalls, frailty, and fractures in the elderly
Falls are among the most common and serious events in older adults and are closely associated with frailty. Falls frequently result in fractures, leading to substantial consequences for health, physical function, quality of life, independence, social isolation, and increased mortality. Although falls are often perceived as an inevitable part of ageing, this review finds that falls can be largely prevented through targeted exercise and their consequences mitigated through a systematic, multidisciplinary approach.
- Open Access
- 23 October 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (1) , 31-41
Shear-wave elastography for muscle assessment in geriatric outpatients at increased risk of falling
Purpose: Sarcopenia, defined by the loss of muscle strength, quantity, and quality, increases the risk of functional decline and adverse outcomes. Shear-wave elastography (SWE), a non-invasive ultrasound-based technique, quantifies muscle stiffness. However, its diagnostic value in sarcopenia remains unclear. This study investigated the relationship between rectus femoris (RF) stiffness and physical performance in geriatric outpatients with and without sarcopenia. Methods: This cross-sectional study, conducted in a geriatric outpatient clinic, included consecutive patients aged ≥ 65 years. Muscle stiffness was assessed using SWE, and muscle thickness was measured to estimate appendicular lean mass (ALM). Sarcopenia was diagnosed per EWGSOP2 criteria. Analyses included group comparisons, multivariable regression, and evaluating diagnostic accuracy using previously suggested SWE thresholds. Results: In total, 114 patients were included (mean age 80 ± 9.9 years; 65.8% female). The prevalence of sarcopenia was 20.1%. No significant difference in SWE was found between sarcopenic and non-sarcopenic participants ( p = 0.78), nor was SWE associated with age ( ρ = − 0.03, p = 0.72). Lower SWE was associated with poor physical performance (short physical performance battery ≤ 7; β = − 1.30, p = 0.025). At Q1 (4.062 kPa), the relative risk (RR) of sarcopenia was 0.83 (95% CI: 0.36–1.90); sensitivity 74%, specificity 22%. At Q3 (8.249 kPa), RR 2.33 (95% CI: 1.09–4.96); sensitivity 26%, specificity 90%. At Youden’s (8.226 kPa), RR 2.68 (95% CI: 1.31–5.47); sensitivity 30.4%, specificity 90.1%. Conclusion: Lower SWE is associated with poor physical performance. SWE is not a reliable standalone marker for sarcopenia in geriatric outpatients. Until stronger evidence emerges, assessing ALM remains preferable.
- 23 October 2025
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (1) , 31-41
Open AccessShear-wave elastography for muscle assessment in geriatric outpatients at increased risk of falling
Purpose: Sarcopenia, defined by the loss of muscle strength, quantity, and quality, increases the risk of functional decline and adverse outcomes. Shear-wave elastography (SWE), a non-invasive ultrasound-based technique, quantifies muscle stiffness. However, its diagnostic value in sarcopenia remains unclear. This study investigated the relationship between rectus femoris (RF) stiffness and physical performance in geriatric outpatients with and without sarcopenia. Methods: This cross-sectional study, conducted in a geriatric outpatient clinic, included consecutive patients aged ≥ 65 years. Muscle stiffness was assessed using SWE, and muscle thickness was measured to estimate appendicular lean mass (ALM). Sarcopenia was diagnosed per EWGSOP2 criteria. Analyses included group comparisons, multivariable regression, and evaluating diagnostic accuracy using previously suggested SWE thresholds. Results: In total, 114 patients were included (mean age 80 ± 9.9 years; 65.8% female). The prevalence of sarcopenia was 20.1%. No significant difference in SWE was found between sarcopenic and non-sarcopenic participants ( p = 0.78), nor was SWE associated with age ( ρ = − 0.03, p = 0.72). Lower SWE was associated with poor physical performance (short physical performance battery ≤ 7; β = − 1.30, p = 0.025). At Q1 (4.062 kPa), the relative risk (RR) of sarcopenia was 0.83 (95% CI: 0.36–1.90); sensitivity 74%, specificity 22%. At Q3 (8.249 kPa), RR 2.33 (95% CI: 1.09–4.96); sensitivity 26%, specificity 90%. At Youden’s (8.226 kPa), RR 2.68 (95% CI: 1.31–5.47); sensitivity 30.4%, specificity 90.1%. Conclusion: Lower SWE is associated with poor physical performance. SWE is not a reliable standalone marker for sarcopenia in geriatric outpatients. Until stronger evidence emerges, assessing ALM remains preferable.
- Open Access
- 11 November 2024
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 260-269
Validation of point-of-care tests used at in-home assessments among older adults in primary care
Diagnosing acute disease in older adults is challenged by vague and atypical symptoms. Point-of-care tests (POCTs) at home may improve diagnostics and clinical decision-making. We compared various POCT devices to routine testing in acutely ill older adults to assess their clinical reliability. We enrolled participants aged 65+ years requiring acute in-home assessment with signs of acute conditions. Venous and capillary blood samples were collected and analysed on-site using POCT, while identical samples were transported and analysed in a routine laboratory. Agreement between POCT and laboratory testing was assessed using scatter plots with linear regression, Pearson's correlation coefficient (PCC), limits of agreement, and Bland-Altman plots. Misclassification rates were calculated based on clinically meaningful cut-offs to assess POCT's clinical reliability. We included 100 participants with a mean age of 81.6 (±8.4 SD) years. Strong correlation was found between POCT and routine measurements (PCC: 0.76-0.94 for capillary samples and 0.85-0.98 for venous samples). Venous samples showed higher PCC than capillary, except for neutrophils (0.93 for capillary, 0.89 for venous). Misclassification occurred in capillary samples for haemoglobin (10/62) and total WBC (6/50), while in venous samples, misclassification was observed for haemoglobin (4/54), total WBC (4/50), K+ (5/47), urea (5/47), and creatinine (3/42). No misclassification was observed for Na+. POCT provides acceptable, clinically reliable measurements in acutely ill older adults, potentially enhancing diagnostics and treatments during in-home assessment. Venous blood testing is preferable due to a lower misclassification rate, but capillary blood remains a pragmatic alternative, despite higher variation and inaccuracy.
- 11 November 2024
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 260-269
Open AccessValidation of point-of-care tests used at in-home assessments among older adults in primary care
Diagnosing acute disease in older adults is challenged by vague and atypical symptoms. Point-of-care tests (POCTs) at home may improve diagnostics and clinical decision-making. We compared various POCT devices to routine testing in acutely ill older adults to assess their clinical reliability. We enrolled participants aged 65+ years requiring acute in-home assessment with signs of acute conditions. Venous and capillary blood samples were collected and analysed on-site using POCT, while identical samples were transported and analysed in a routine laboratory. Agreement between POCT and laboratory testing was assessed using scatter plots with linear regression, Pearson's correlation coefficient (PCC), limits of agreement, and Bland-Altman plots. Misclassification rates were calculated based on clinically meaningful cut-offs to assess POCT's clinical reliability. We included 100 participants with a mean age of 81.6 (±8.4 SD) years. Strong correlation was found between POCT and routine measurements (PCC: 0.76-0.94 for capillary samples and 0.85-0.98 for venous samples). Venous samples showed higher PCC than capillary, except for neutrophils (0.93 for capillary, 0.89 for venous). Misclassification occurred in capillary samples for haemoglobin (10/62) and total WBC (6/50), while in venous samples, misclassification was observed for haemoglobin (4/54), total WBC (4/50), K+ (5/47), urea (5/47), and creatinine (3/42). No misclassification was observed for Na+. POCT provides acceptable, clinically reliable measurements in acutely ill older adults, potentially enhancing diagnostics and treatments during in-home assessment. Venous blood testing is preferable due to a lower misclassification rate, but capillary blood remains a pragmatic alternative, despite higher variation and inaccuracy.
- 2 July 2023
- Published by Springer Nature in European Geriatric Medicine
- Vol. 14 (4) , 747-760
Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review
Key summary points AbstractSection Aim To examine whether and how osteoporosis guidelines include recommendations on deprescribing of bisphosphonates. AbstractSection Findings Osteoporosis guidelines include limited guidance on how to make individualized deprescribing decisions based on individual health context. AbstractSection Message More detailed deprescribing guidance may be warranted in osteoporosis guidelines to help prescribers and patients/caregivers make individualized decisions about bisphosphonate therapy for older persons. This should include considerations of treatment goals/preferences, assessment of life expectancy, and weighing benefits/risks of continuation versus deprescribing.
- 2 July 2023
- Published by Springer Nature in European Geriatric Medicine
- Vol. 14 (4) , 747-760
Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review
Key summary points AbstractSection Aim To examine whether and how osteoporosis guidelines include recommendations on deprescribing of bisphosphonates. AbstractSection Findings Osteoporosis guidelines include limited guidance on how to make individualized deprescribing decisions based on individual health context. AbstractSection Message More detailed deprescribing guidance may be warranted in osteoporosis guidelines to help prescribers and patients/caregivers make individualized decisions about bisphosphonate therapy for older persons. This should include considerations of treatment goals/preferences, assessment of life expectancy, and weighing benefits/risks of continuation versus deprescribing.
- Open Access
- 5 September 2020
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 12 (1) , 1-9
The combined effect of parathyroid hormone (1–34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial
Background: The aim of this study was to investigate the effect on physical performance of combining whole-body vibration exercise (WBV) with parathyroid hormone 1–34 (teriparatide) compared to teriparatide alone. Methods: A secondary analysis from a RCT where postmenopausal women with severe osteoporosis were randomised to WBV plus teriparatide (intervention) or teriparatide alone (control). WBV was applied three times/week (6x1min WBV:1 min rest, (peak acceleration 3.6 g)) for twelve months. Both groups received teriparatide 20 μg s.c./day. The primary endpoint (bone mineral density) is reported elsewhere. Physical performance measures (Short Physical Performance Battery (SPPB), Timed-Up-and-Go (TUG), leg extension power, and grip strength) were obtained at baseline, three-, six-, and twelve months, lean mass at baseline and twelve months. Data were analysed with mixed linear regression model or robust cluster regression in an intention to treat analysis. Results: Thirty-five women aged (mean ± SD) 69 ± 7) years were recruited of which thirty-two (91%) completed the twelve months follow-up (WBV + teriparatide = 15, teriparatide = 17). SPPB score (mean ± SD) improved significantly at three months in the WBV + teriparatide group from 9.13 ± 2.03 to 10.35 ± 1.69 (p = 0.014) with a statistical trend towards a between-group change in favor of the WBV + teriparatide group (0.86 [95%CI(− 0.05,1.77), p = 0.065]). Both groups improved in leg extension power during the study period whereas no changes were seen in TUG, grip strength, or lean mass in either group. No statistical significant between-group differences were observed. Conclusion: WBV may improve some short-term aspects of physical performance in severely osteoporotic postmenopausal women who are receiving teriparatide treatment. Trial Registration: ClinicalTrials.gov, ID:NCT02563353
- 5 September 2020
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 12 (1) , 1-9
Open AccessThe combined effect of parathyroid hormone (1–34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial
Background: The aim of this study was to investigate the effect on physical performance of combining whole-body vibration exercise (WBV) with parathyroid hormone 1–34 (teriparatide) compared to teriparatide alone. Methods: A secondary analysis from a RCT where postmenopausal women with severe osteoporosis were randomised to WBV plus teriparatide (intervention) or teriparatide alone (control). WBV was applied three times/week (6x1min WBV:1 min rest, (peak acceleration 3.6 g)) for twelve months. Both groups received teriparatide 20 μg s.c./day. The primary endpoint (bone mineral density) is reported elsewhere. Physical performance measures (Short Physical Performance Battery (SPPB), Timed-Up-and-Go (TUG), leg extension power, and grip strength) were obtained at baseline, three-, six-, and twelve months, lean mass at baseline and twelve months. Data were analysed with mixed linear regression model or robust cluster regression in an intention to treat analysis. Results: Thirty-five women aged (mean ± SD) 69 ± 7) years were recruited of which thirty-two (91%) completed the twelve months follow-up (WBV + teriparatide = 15, teriparatide = 17). SPPB score (mean ± SD) improved significantly at three months in the WBV + teriparatide group from 9.13 ± 2.03 to 10.35 ± 1.69 (p = 0.014) with a statistical trend towards a between-group change in favor of the WBV + teriparatide group (0.86 [95%CI(− 0.05,1.77), p = 0.065]). Both groups improved in leg extension power during the study period whereas no changes were seen in TUG, grip strength, or lean mass in either group. No statistical significant between-group differences were observed. Conclusion: WBV may improve some short-term aspects of physical performance in severely osteoporotic postmenopausal women who are receiving teriparatide treatment. Trial Registration: ClinicalTrials.gov, ID:NCT02563353
- Open Access
- 15 July 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (9) , 1827-1836
The combined effect of Parathyroid hormone (1–34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial
Summary Treatment effects of combining teriparatide and whole-body vibration exercise (WBV) vs teriparatide alone in twelve months were compared using bone mineral density (BMD), bone microarchitecture, and bone turnover markers. We found an increased effect in lumbar spine BMD by adding WBV to teriparatide in postmenopausal osteoporotic women. Introduction The parathyroid hormone (PTH) analogue teriparatide is an effective but expensive anabolic treatment for osteoporosis. Whole-body vibration exercise (WBV) has been found to stimulate muscle and bone strength in some studies. Animal data demonstrate a beneficial effect on bone when combining PTH with mechanical loading. The aim of this study was to investigate if combining WBV exercise and teriparatide treatment gives additional beneficial effects on bone compared to teriparatide alone in postmenopausal women with osteoporosis. Methods The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone. WBV consisted of three sessions a week (12 min, including 1:1 ratio of exercise:rest). Bone mineral density (BMD) and bone microarchitecture, bone turnover markers, and sclerostin measurements were obtained. Data were analyzed using a linear mixed regression model with adjustment for baseline values or robust cluster regression in an intention-to-treat (ITT) analysis. Results Thirty-five women were randomized (17 in teriparatide + WBV group and 18 in teriparatide group). At 12 months, both groups increased significantly in BMD at the lumbar spine. The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51. The adjusted treatment effect of adding WBV to teriparatide was statistically significant at 2.95% [95% CI = 0.14–5.77; P = 0.040]. Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups. No other treatment effects were observed in hip BMD, bone microarchitecture parameters, or sclerostin levels in either group. Conclusion Twelve months of WBV and teriparatide had a significant clinically relevant treatment effect in lumbar spine BMD compared to teriparatide alone in postmenopausal osteoporotic women. ClinicalTrials.gov:(NCT02563353).
- 15 July 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (9) , 1827-1836
Open AccessThe combined effect of Parathyroid hormone (1–34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial
Summary Treatment effects of combining teriparatide and whole-body vibration exercise (WBV) vs teriparatide alone in twelve months were compared using bone mineral density (BMD), bone microarchitecture, and bone turnover markers. We found an increased effect in lumbar spine BMD by adding WBV to teriparatide in postmenopausal osteoporotic women. Introduction The parathyroid hormone (PTH) analogue teriparatide is an effective but expensive anabolic treatment for osteoporosis. Whole-body vibration exercise (WBV) has been found to stimulate muscle and bone strength in some studies. Animal data demonstrate a beneficial effect on bone when combining PTH with mechanical loading. The aim of this study was to investigate if combining WBV exercise and teriparatide treatment gives additional beneficial effects on bone compared to teriparatide alone in postmenopausal women with osteoporosis. Methods The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone. WBV consisted of three sessions a week (12 min, including 1:1 ratio of exercise:rest). Bone mineral density (BMD) and bone microarchitecture, bone turnover markers, and sclerostin measurements were obtained. Data were analyzed using a linear mixed regression model with adjustment for baseline values or robust cluster regression in an intention-to-treat (ITT) analysis. Results Thirty-five women were randomized (17 in teriparatide + WBV group and 18 in teriparatide group). At 12 months, both groups increased significantly in BMD at the lumbar spine. The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51. The adjusted treatment effect of adding WBV to teriparatide was statistically significant at 2.95% [95% CI = 0.14–5.77; P = 0.040]. Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups. No other treatment effects were observed in hip BMD, bone microarchitecture parameters, or sclerostin levels in either group. Conclusion Twelve months of WBV and teriparatide had a significant clinically relevant treatment effect in lumbar spine BMD compared to teriparatide alone in postmenopausal osteoporotic women. ClinicalTrials.gov:(NCT02563353).
- 30 January 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (5) , 1459-1475
Is calcaneal quantitative ultrasound useful as a prescreen stratification tool for osteoporosis?
Calcaneal quantitative ultrasound (QUS) is attractive as a prescreening tool for osteoporosis, alternative to dual-energy X-ray absorptiometry. We investigated the literature of the usability of calcaneal QUS. We found large heterogeneity between studies and uncertainty about cutoff, device, and measured variable. Despite osteoporosis-related fractures being a major health issue, osteoporosis remains underdiagnosed. Dual-energy X-ray absorptiometry (DXA) of the hip or spine is currently the preferred method for diagnosis of osteoporosis, but the method is limited by low accessibility. QUS is a method for assessing bone alternative to DXA. The aim of this systematic review was to explore the usability of QUS as a prescreen stratification tool for assessment of osteoporosis. Studies that evaluated calcaneal QUS with DXA of the hip or spine as the gold standard was included. We extracted data from included studies to calculate number of DXAs saved and misclassification rates at cutoffs equal to high sensitivity and/or specificity. The number of DXAs saved and percentage of persons misclassified were measures of usability. We included 31 studies. Studies were heterogeneous regarding study characteristics. Analyses showed a wide spectrum of percentage of DXAs saved (2.7–68.8 %) and misclassification rates (0–12.4 %) depending on prescreen strategy and study characteristics, device, measured variable, and cutoff. Calcaneal QUS is potentially useful as a prescreen tool for assessment of osteoporosis. However, there is no consensus of device, variable, and cutoff. Overall, there is no sufficient evidence to recommend a specific cutoff for calcaneal QUS that provides a certainty level high enough to rule in or out osteoporosis. Calcaneal QUS in a prescreen or stratification algorithm must be based on device-specific cutoffs that are validated in the populations for which they are intended to be used.
- 30 January 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (5) , 1459-1475
Is calcaneal quantitative ultrasound useful as a prescreen stratification tool for osteoporosis?
Calcaneal quantitative ultrasound (QUS) is attractive as a prescreening tool for osteoporosis, alternative to dual-energy X-ray absorptiometry. We investigated the literature of the usability of calcaneal QUS. We found large heterogeneity between studies and uncertainty about cutoff, device, and measured variable. Despite osteoporosis-related fractures being a major health issue, osteoporosis remains underdiagnosed. Dual-energy X-ray absorptiometry (DXA) of the hip or spine is currently the preferred method for diagnosis of osteoporosis, but the method is limited by low accessibility. QUS is a method for assessing bone alternative to DXA. The aim of this systematic review was to explore the usability of QUS as a prescreen stratification tool for assessment of osteoporosis. Studies that evaluated calcaneal QUS with DXA of the hip or spine as the gold standard was included. We extracted data from included studies to calculate number of DXAs saved and misclassification rates at cutoffs equal to high sensitivity and/or specificity. The number of DXAs saved and percentage of persons misclassified were measures of usability. We included 31 studies. Studies were heterogeneous regarding study characteristics. Analyses showed a wide spectrum of percentage of DXAs saved (2.7–68.8 %) and misclassification rates (0–12.4 %) depending on prescreen strategy and study characteristics, device, measured variable, and cutoff. Calcaneal QUS is potentially useful as a prescreen tool for assessment of osteoporosis. However, there is no consensus of device, variable, and cutoff. Overall, there is no sufficient evidence to recommend a specific cutoff for calcaneal QUS that provides a certainty level high enough to rule in or out osteoporosis. Calcaneal QUS in a prescreen or stratification algorithm must be based on device-specific cutoffs that are validated in the populations for which they are intended to be used.
- 1 June 2013
- Published by Elsevier in The American Journal of Medicine
- Vol. 126 (6) , e13-e14
Increased Mortality in Geriatric Patients with Hospital-acquired Hypernatremia
- 1 June 2013
- Published by Elsevier in The American Journal of Medicine
- Vol. 126 (6) , e13-e14
Increased Mortality in Geriatric Patients with Hospital-acquired Hypernatremia
- Open Access
- 25 June 2012
- Published by Springer Nature in BMC Geriatrics
- Vol. 12 (1) , 32
Functional level at admission is a predictor of survival in older patients admitted to an acute geriatric unit
Functional decline is associated with increased risk of mortality in geriatric patients. Assessment of activities of daily living (ADL) with the Barthel Index (BI) at admission was studied as a predictor of survival in older patients admitted to an acute geriatric unit.
- 25 June 2012
- Published by Springer Nature in BMC Geriatrics
- Vol. 12 (1) , 32
Open AccessFunctional level at admission is a predictor of survival in older patients admitted to an acute geriatric unit
Functional decline is associated with increased risk of mortality in geriatric patients. Assessment of activities of daily living (ADL) with the Barthel Index (BI) at admission was studied as a predictor of survival in older patients admitted to an acute geriatric unit.